Novartis’ Kisqali prevents breast cancer from coming back for longer — but can it best Eli Lilly’s Verzenio? #ASCO23

Lei Lei Wu

News Reporter

CHICAGO — Novartis’ CDK4/6 inhibitor Kisqali helped early breast cancer patients stay cancer-free for longer after surgery, according to interim study results presented at ASCO. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis’ Kisqali prevents breast cancer from coming back for longer — but can it best Eli Lilly’s Verzenio? #ASCO23

Lei Lei Wu

News Reporter

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

China’s biotech market is staging a comeback that US biotech can only wish for

Large vaccine makers stand by their investments despite US headwinds

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

Genentech vet launches ADC startup with $20M

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

No­var­tis’ Kisqali pre­vents breast can­cer from com­ing back for longer — but can it best Eli Lil­ly’s Verzenio? #AS­CO23

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Novartis’ Kisqali prevents breast cancer from coming back for longer — but can it best Eli Lilly’s Verzenio? #ASCO23